Rapoport Sarah K, Murry Thomas, Woo Peak
Department of Otolaryngology Head and Neck Surgery Mount Sinai Medical Center New York New York USA.
Department of Otolaryngology-Head and Neck Surgery Loma Linda Health University Loma Linda California USA.
Laryngoscope Investig Otolaryngol. 2021 May 27;6(3):453-457. doi: 10.1002/lio2.573. eCollection 2021 Jun.
Compare long-term voice outcomes in patients treated with FIM or BML for nonparalytic dysphonia. There is controversy whether fat injection medialization (FIM) is a durable alternative to bilateral medialization laryngoplasty (BML) for nonparalytic dysphonia (atrophy, sulcus, scar, paresis). Both interventions yield improved voice quality, yet comparison of patients' long-term perceptions of their voice after these procedures has not been performed.
Retrospective review of patients who underwent FIM or BML for nonparalytic dysphonia was performed from 2008-2018. Charts were reviewed for demographic information, preoperative diagnosis, intervention, Voice Handicap Index-10 (VHI-10), and follow-up time.
Forty-nine patients met our criteria. Fifty procedures were performed (25 FIM, 25 BML). One patient underwent BML with subsequent FIM. There was no significant difference in pre-treatment or post-treatment VHI-10 scores between both groups (Pre-FIM 21 Post-FIM 10.28; Pre-BML 22.48, Post-BML 10.88). Total median follow-up time was 11.3 months (FIM 14.8 months, BML 9.5 months). Using VHI-10 scores recorded at each patient's latest follow-up visit, both groups demonstrated significant decrease ( < .05) compared to preoperative scores: VHI-10 decreased by a mean delta of 10.72 in the FIM group and 11.6 in the BML group. There was no significant difference in pre, post and change in VHI between groups.
In patients with nonparalytic dysphonia, FIM is a durable alternative to BML. Patients treated in both groups gained substantial improvement in vocal function. For both treatment groups, we should anticipate less than complete satisfaction with surgery and revision procedures in a minority of patients.
IV.
比较接受脂肪注射喉内移植物植入术(FIM)或双侧喉内移植物成形术(BML)治疗的非麻痹性发音障碍患者的长期嗓音结局。对于非麻痹性发音障碍(萎缩、沟裂、瘢痕、轻瘫),脂肪注射喉内移植物植入术(FIM)是否是双侧喉内移植物成形术(BML)的持久替代方法存在争议。两种干预措施均能改善嗓音质量,但尚未对患者在这些手术后对其嗓音的长期感知进行比较。
对2008年至2018年接受FIM或BML治疗非麻痹性发音障碍的患者进行回顾性研究。查阅病历以获取人口统计学信息、术前诊断、干预措施、嗓音障碍指数-10(VHI-10)和随访时间。
49例患者符合我们的标准。共进行了50次手术(25次FIM,25次BML)。1例患者先接受了BML,随后接受了FIM。两组治疗前和治疗后的VHI-10评分无显著差异(FIM术前21,FIM术后10.28;BML术前22.48,BML术后10.88)。总中位随访时间为11.3个月(FIM为14.8个月,BML为9.5个月)。使用每位患者最近一次随访时记录的VHI-10评分,与术前评分相比,两组均显示出显著下降(P<0.05):FIM组VHI-10平均下降差值为10.72,BML组为11.6。两组之间VHI的术前、术后及变化无显著差异。
在非麻痹性发音障碍患者中,FIM是BML的一种持久替代方法。两组接受治疗的患者嗓音功能均有显著改善。对于两个治疗组,我们应预计少数患者对手术和翻修手术的满意度不完全。
IV级